Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two- Sequence, Single-Dose, Crossover Bioavailability Study Comparing Hydrochlorothiazide 50 mg Tablet of Ohm Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals USA) With Hydrochlorothiazide 50 mg Tablet of IVAX Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fasting Condition

NCT00776646 is registered in ClinicalTrials.gov with Ranbaxy Laboratories Limited as lead sponsor.

NCT NCT00776646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two- Sequence, Single-Dose, Crossover Bioavailability Study Comparing Hydrochlorothiazide 50 mg Tablet of Ohm Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals USA) With Hydrochlorothiazide 50 mg Tablet of IVAX Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fasting Condition
Lead sponsor
Ranbaxy Laboratories Limited
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2006
Completion date
August 31, 2006
Enrollment
36 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy